There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
-
BUSINESS BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
-
BUSINESS US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
-
REGULATORY 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
-
REGULATORY Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
-
REGULATORY MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
-
REGULATORY Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
-
REGULATORY 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
-
BUSINESS Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
-
BUSINESS AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
-
ORGANIZATION PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
-
BUSINESS Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
-
BUSINESS Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
-
REGULATORY Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
-
BUSINESS Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
-
BUSINESS Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
-
BUSINESS Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
-
COMMENTARY Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
-
ACADEMIA Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
May 9, 2022
-
REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…